Interferon-alpha versus somatostatin or the combination of both in metastatic neuroendocrine gut and pancreatic tumours.
Neuroendocrine tumours of the gastroenteropancreatic system represent a therapeutic challenge. Current therapeutic strategies will be presented and discussed with especial consideration given to biotherapeutic regimens in metastatic tumour disease.